- Home
- DXLG vs KRRO Comparison
DXLG vs KRRO Comparison
Compare DXLG & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | KRRO |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.6M | 58.6M |
| IPO Year | 1987 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DXLG | KRRO |
|---|---|---|
| Price | $1.14 | $7.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $2.50 | ★ $74.17 |
| AVG Volume (30 Days) | 70.8K | ★ 1.1M |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $447,744,000.00 | $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | $3.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.88 | $5.20 |
| 52 Week High | $3.10 | $55.89 |
Technical Indicators
Market Signals| Indicator | DXLG | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 27.15 |
| Support Level | $0.90 | $5.20 |
| Resistance Level | $1.00 | $6.59 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | 0.03 | 0.75 |
| Stochastic Oscillator | 74.29 | 89.19 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.